Bristol-Myers Squibb Co. has made changes to its U.S. geographic footprint aimed at strengthening capabilities of its R&D hubs in Central NJ, the San Francisco Bay Area and Cambridge, MA, while further integrating biologics development with clinical manufacturing at key sites. Previous investments include the development of a state-of-the-art research facility in Cambridge, the expansion of its Redwood City research campus in the San Francisco and the recently opened Princeton Pike facility ...